Literature DB >> 7957051

Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells.

Y Wu1, Y Liu, L Lee, Z Miner, M Kulesz-Martin.   

Abstract

A p53 variant protein (p53as) generated from alternatively spliced p53 RNA is expressed in normal and malignant mouse cells and tissues, and p53as antigen activity is preferentially associated with the G2 phase of the cell cycle, suggesting that p53as and p53 protein may have distinct properties. Using p53as and p53 proteins translated in vitro, we now provide evidence that p53as protein has efficient sequence-specific DNA-binding ability. DNA binding by p53 protein is inefficient in comparison and requires activation. Furthermore, p53as and p53 proteins formed hetero-oligomers when co-translated in vitro, resulting in inactivation of p53as DNA-binding activity. Gel filtration indicated that p53as translated in vitro, like p53, formed tetramers. In support of a functional role of p53as in cells, p53as/p53 hetero-oligomers were coimmunoprecipitated from mouse cells, and both protein forms were detectable in nuclear extracts by electrophoretic mobility shift assays. These results suggest that the biochemical functions of p53 are mediated by interaction between two endogenous protein products of the wild-type p53 gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7957051      PMCID: PMC395421          DOI: 10.1002/j.1460-2075.1994.tb06808.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  38 in total

1.  Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation.

Authors:  J Milner; E A Medcalf
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

2.  A transcriptionally active DNA-binding site for human p53 protein complexes.

Authors:  W D Funk; D T Pak; R H Karas; W E Wright; J W Shay
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

3.  Alternatively spliced p53 RNA in transformed and normal cells of different tissue types.

Authors:  K A Han; M F Kulesz-Martin
Journal:  Nucleic Acids Res       Date:  1992-04-25       Impact factor: 16.971

4.  Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo.

Authors:  A B Lassar; R L Davis; W E Wright; T Kadesch; C Murre; A Voronova; D Baltimore; H Weintraub
Journal:  Cell       Date:  1991-07-26       Impact factor: 41.582

5.  Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication.

Authors:  J Bargonetti; P N Friedman; S E Kern; B Vogelstein; C Prives
Journal:  Cell       Date:  1991-06-14       Impact factor: 41.582

6.  Mammalian p53 can function as a transcription factor in yeast.

Authors:  E Schärer; R Iggo
Journal:  Nucleic Acids Res       Date:  1992-04-11       Impact factor: 16.971

7.  Isolation of a full-length mouse cDNA clone coding for an immunologically distinct p53 molecule.

Authors:  D Wolf; N Harris; N Goldfinger; V Rotter
Journal:  Mol Cell Biol       Date:  1985-01       Impact factor: 4.272

8.  Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells.

Authors:  M F Kulesz-Martin; B Lisafeld; H Huang; N D Kisiel; L Lee
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

9.  Identification of p53 as a sequence-specific DNA-binding protein.

Authors:  S E Kern; K W Kinzler; A Bruskin; D Jarosz; P Friedman; C Prives; B Vogelstein
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

10.  Participation of p53 protein in the cellular response to DNA damage.

Authors:  M B Kastan; O Onyekwere; D Sidransky; B Vogelstein; R W Craig
Journal:  Cancer Res       Date:  1991-12-01       Impact factor: 12.701

View more
  15 in total

1.  Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53.

Authors:  Y Wu; H Huang; Z Miner; M Kulesz-Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

2.  Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.

Authors:  S Kaku; Y Iwahashi; A Kuraishi; A Albor; T Yamagishi; S Nakaike; M Kulesz-Martin
Journal:  Nucleic Acids Res       Date:  2001-05-01       Impact factor: 16.971

3.  The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells.

Authors:  N Almog; R Li; A Peled; D Schwartz; R Wolkowicz; N Goldfinger; H Pei; V Rotter
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

4.  DNA binding specificity of proteins derived from alternatively spliced mouse p53 mRNAs.

Authors:  Z Miner; M Kulesz-Martin
Journal:  Nucleic Acids Res       Date:  1997-04-01       Impact factor: 16.971

5.  Regulated expression and RNA processing of transcripts from the Srp20 splicing factor gene during the cell cycle.

Authors:  H Jumaa; J L Guénet; P J Nielsen
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

6.  Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene.

Authors:  M Laverdière; J Beaudoin; A Lavigueur
Journal:  Nucleic Acids Res       Date:  2000-03-15       Impact factor: 16.971

Review 7.  Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells.

Authors:  H D Lohrer
Journal:  Experientia       Date:  1996-04-15

8.  p53 isoforms can regulate p53 transcriptional activity.

Authors:  Jean-Christophe Bourdon; Kenneth Fernandes; Fiona Murray-Zmijewski; Geng Liu; Alexandra Diot; Dimitris P Xirodimas; Mark K Saville; David P Lane
Journal:  Genes Dev       Date:  2005-08-30       Impact factor: 11.361

9.  Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form.

Authors:  R Wolkowicz; A Peled; N B Elkind; V Rotter
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

10.  Species- and tissue-specific expression of the C-terminal alternatively spliced form of the tumor suppressor p53.

Authors:  K Will; G Warnecke; S Bergmann; W Deppert
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.